Highlights from a recent BIO survey on therapeutic protein - Drug interactions

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1755-1763

  Lloyd, Peter ^a   Zhou, Honghui ^b   Theil, Frank Peter ^c   Kakkar, Tarundeep ^d   Nestorov, Ivan ^e   Roberts, Stanley A ^f  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CENTOCOR INC   (United States)

^c GENENTECH INC   (United States)

^d AMGEN INC   (United States)

^e BIOGEN   (United States)

^f SAR Safety Assessment   (United States)

Author keywords

clinical pharmacology; Drug drug interactions, biopharmaceutics; pharmaceutical R D; pharmacokinetics and drug metabolism

Indexed keywords

CYTOCHROME P450; CYTOKINE; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT PROTEIN; SIMVASTATIN; TOCILIZUMAB;

BIOTECHNOLOGY; CLINICAL PHARMACOLOGY; CLINICAL STUDY; CYTOKINE RELEASE; DRUG INDUSTRY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; LIVER CELL; MACROMOLECULE; MOLECULAR WEIGHT; ORGANIZATION; QUESTIONNAIRE; REVIEW;

DATA COLLECTION; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 84868013997     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011424144     Document Type: Review

References (12)

1. Food and Drug Administration. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: Food and Drug Administration; September2006. http://www.fda.gov/ cder/guidance/index.htm
2. European Medicines Agency (EMA). EMA Guideline on the Investigation of Drug Interactions. London: April2010; EMA. www.ema.europa.eu
3. Mahmood I, Green MD.. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharm. 2007 ; 47: 1540-1554 (Pubitemid 350115304)
4. Seitz K, Zhou H.. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharm. 2007 ; 47: 1104-1118
5. Huang S-M, Zhao H, Lee J-I, et al. Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther. 2010 ; 87: 497-503
6. Lee J-I, Zhang L, Men AY, Kenna LA, Huang S-M.. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet. 2010 ; 49: 295-310
7. Zhou H, Mascelli MA.. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011 ; 51: 359-372
8. Zhou H.. A recent BIO survey of therapeutic protein-drug interaction evaluation. Presented at: AAPS Workshop on Strategies to Address TPDI During Clinical Development ; San Francisco, CA ;..
9. Zhou H.. An industrial perspective on drug interactions with biologics. Presented at: Thirteenth Annual Land O'Lakes Conference on Drug Metabolism/Applied Pharmacokinetics ; Devils Head Resort, Merrimac, WI ;..
10. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 ; 41: 1552-1563 (Pubitemid 28459913)
11. Morgan ET.. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009 ; 85: 434-438
12. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S.. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011 ; 89: 735-740